I hereby certify that this paper is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 847894453 US, on the date shown below in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box

1450, Alexandria, VA 22313-1450.

ed: September 29, 2008 Signature:

Patent Docket No. 532212000623

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Thomas L. CANTOR et al.

Serial No.: 10/617,489

Filing Date: July 10, 2003

For: METHODS, KITS AND ANTIBODIES

FOR DETECTING PARATHYROID

HORMONE

Examiner: C. Cheu

Group Art Unit: 1641

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER MPEP § 724.02

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to the duty of disclosure in 37 C.F.R. § 1.56, Applicants hereby submit under MPEP § 724.02 the 28 documents listed on the attached Form PTO/SB/08a/b. The attention of the Patent and Trademark Office is hereby directed to these documents because they are **SUBJECT TO PROTECTIVE ORDER**. It is respectfully requested that the Examiner consider the information during the prosecution of this application.

The document numbers 1-28 listed on the attached Form PTO/SB/08a/b are **SUBJECT TO PROTECTIVE ORDER** and should only be viewed by the Examiner or other authorized
Patent and Trademark Office Employees. Pursuant to MPEP § 724.02, a copy of each document

that is **SUBJECT TO PROTECTIVE ORDER** listed on the attached Form PTO/SB/08a/b is enclosed in a sealed, clearly labeled envelope.

Document numbers 1-28 are from *Scantibodies Laboratory, Inc. v. Immutopics, Inc.*, from the United States District Court for the Central District of California, Case No. CV 04-08871 MRP (MANx), now appealed at the United States Court of Appeals for the Federal Circuit, Case No. 2008-1522. This litigation involves U.S. Patent No. 6,689,566. The present application is a Continuation-in-Part of U.S. Patent No. 6,743,590, which is a Continuation-in-Part of U.S. Patent No. 6,689,566. Scantibodies Laboratory, Inc. is the assignee of U.S. Patent No. 6,689,566 and the present application.

Note that information designated by Immutopics as "Confidential" or "Confidential-Attorneys' Eyes Only" has been redacted from document numbers 3, 7, 17, 18, 19, 20, and 22 on the attached Form PTO/SB/08a/b.

This Information Disclosure Statement is submitted:

	With the application; accordingly, no fee or separate requirements are required.	
\boxtimes	Before	the mailing of a first Office Action after the filing of a Request for Continued
	Exami	nation under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97
	(e)(1)	has been provided.
	Within three months of the application filing date or before mailing of a first Office Action	
	on the	merits; accordingly, no fee or separate requirements are required. However, if
	applic	able, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
	After receipt of a first Office Action on the merits but before mailing of a final Office Action	
	or Notice of Allowance.	
		A fee is required. A check in the amount of is enclosed.
		A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to
		this submission in duplicate.
		A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is
		believed to be due.

After	mailing of a final Office Action or Notice of Allowance, but before payment of the		
issue	issue fee.		
	A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the		
	amount of is enclosed.		
	A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal		
	form (PTO/SB/17 is attached to this submission in duplicate.)		

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 532212000623.

Dated: September 29, 2008

Respectfully submitted,

Peng Chen

By

Registration No.: 43,543
MORRISON & FOERSTER LLP
12531 High Bluff Drive, Suite 100

San Diego, California 92130-2040

(858) 720-5117